HYL Hyloris Pharmaceuticals SA

4.562USD4.150 EUR · EBR-3.49%Mkt Cap: 127.73M USDP/E: —

Hyloris Pharmaceuticals SA operates as a specialty pharmaceutical company in Belgium, the United States, Europe, the Middle East, Africa, and Asia-Pacific. The company offers Maxigesic IV for the treatment of post-operat…

Key Statistics

Company
Market Cap127.73M USD
Enterprise Value114.19M USD
Revenue (TTM)10.80M USD
Gross Profit7.51M USD
Net Income (TTM)-6.96M USD
Revenue/Share0.39 USD
Last Price4.562 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees54
CountryBE
SectorHealthcare
IndustryBiotechnology
ISINBE0974363955
Valuation
P/E (Trailing)—
P/E (Forward)-20.75
PEG—
EV/EBITDA-17.77
EV/Revenue10.57
P/S11.82
P/B4.46
EPS (TTM)-0.19 USD
EPS (Forward)-0.22 USD
52W Range
3.64916% of range9.233
52W High9.233 USD
52W Low3.649 USD
Profitability
Gross Margin94.74%
Oper. Margin-61.43%
EBITDA Margin-59.48%
Profit Margin-87.89%
ROE-23.92%
ROA-18.99%
ROIC-50.87%
ROCE-27.31%
Growth
Revenue Growth56.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.68M USD
CapEx (TTM)691.40K USD
FCF Margin-89.50%
FCF Yield-7.57%
Net Debt-8.00M USD
Net Debt/EBITDA1.24
Net Debt/FCF—
Balance Sheet
Debt/Equity0.06
Current Ratio4.82
Quick Ratio4.64
Book Value/Sh1.02 USD
Cash/Share0.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.35 USD
Upside (mean)+170.7%
Target Range6.595 USD – 18.91 USD
6.595+170.7% to mean18.91
# Analysts3
Ownership
Shares Out.28.00M
Float24.76M
Insiders55.76%
Institutions0.00%
Technical
SMA 504.476 (+1.9%)
SMA 2005.398 (-15.5%)
Beta0.65
S&P 52W Chg8.68%
Avg Vol (30d)9.63K
Avg Vol (10d)11.11K
Technical Indicators
RSI (14)53.3
MACD0.0557
MACD Signal0.0053
MACD Hist.+0.0505
BB Upper4.932 USD
BB Middle4.336 USD
BB Lower3.740 USD
BB Width27.48%
ATR (14)0.2558 USD
Vol Ratio (20d)0.29x

About Hyloris Pharmaceuticals (EBR: HYL)

›

Hyloris Pharmaceuticals (EBR: HYL) is listed on Euronext Brussels, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 54 employees.

The shares were at 4.150 EUR on 20 November 2026, down 29.7% over 52 weeks. Its 52-week range is 3.320 EUR to 8.400 EUR: the price is 50.6% below the high and 25.0% above the low.

Its market capitalisation is 116.20M EUR.

Hyloris Pharmaceuticals reports return on equity of -23.9%, an operating margin of -61.4% and revenue up 56.5% year over year.

It holds more cash than debt, a net cash position of 7.27M EUR. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 11.23 EUR is 170.7% above the current price. The next earnings report is expected on 25 March 2027.